Yervoy (ipilimumab) - BMS
Tyvyt (sintilimab) - Innovent Biologics, Eli Lilly
Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial (clinicaltrials.gov) - Oct 20, 2026 - P2/3 | N=120 | Not yet recruiting | Sponsor: Yao Hongwei 
New P2/3 trial • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Rectal Cancer • Solid Tumor
http://clinicaltrials.gov/ct2/show/NCT07879586
 
Oct 20, 2026
 
Prev Next